Skip to main content

Novel chemotherapeutic agent FX-9 activates NF-κB signaling and induces G1 phase arrest by activating CDKN1A in a human prostate cancer cell line



The aminoisoquinoline FX-9 shows pro-apoptotic and antimitotic effects against lymphoblastic leukemia cells and prostate adenocarcinoma cells. In contrast, decreased cytotoxic effects against non-neoplastic blood cells, chondrocytes, and fibroblasts were observed. However, the actual FX-9 molecular mode of action is currently not fully understood.


In this study, microarray gene expression analysis comparing FX-9 exposed and unexposed prostate cancer cells (PC-3 representing castration-resistant prostate cancer), followed by pathway analysis and gene annotation to functional processes were performed. Immunocytochemistry staining was performed with selected targets.


Expression analysis revealed 0.83% of 21,448 differential expressed genes (DEGs) after 6-h exposure of FX-9 and 0.68% DEGs after 12-h exposure thereof. Functional annotation showed that FX-9 primarily caused an activation of inflammatory response by non-canonical nuclear factor-kappa B (NF-κB) signaling. The 6-h samples showed activation of the cell cycle inhibitor CDKN1A which might be involved in the secondary response in 12-h samples. This secondary response predominantly consisted of cell cycle-related changes, with further activation of CDKN1A and inhibition of the transcription factor E2F1, including downstream target genes, resulting in G1-phase arrest. Matching our previous observations on cellular level senescence signaling pathways were also found enriched. To verify these results immunocytochemical staining of p21 Waf1/Cip1 (CDKN1A), E2F1 (E2F1), PAI-1 (SERPNE1), and NFkB2/NFkB p 100 (NFKB2) was performed. Increased expression of p21 Waf1/Cip1 and NFkB2/NFkB p 100 after 24-h exposure to FX-9 was shown. E2F1 and PAI-1 showed no increased expression.


FX-9 induced G1-phase arrest of PC-3 cells through activation of the cell cycle inhibitor CDKN1A, which was initiated by an inflammatory response of noncanonical NF-κB signaling.

Peer Review reports


The amino-substituted isoquinoline FX-9 (3-(p-Tolyl)isoquinolin-1-amine) [1] belongs to a substance family showing antimalarial [2], and antifungal [3] properties as well as activity against different tumors [4,5,6]. Previous studies by us proved anti-proliferative effects of FX-9 on hematological and solid tumor cell lines. This effect was accompanied with morphological changes and apoptosis in lymphoblastic leukemia cells, while cytotoxicity and hemolytic activity against non-neoplastic blood cells were not observed [7]. Furthermore, the effects on prostate cancer cells lines of human and canine origin were pro-apoptotic and antimitotic. This was evaluated by analyzing cell viability, total cell number, cell morphological changes and induction of apoptosis [8]. FX-9-mediated cytotoxic activity in non-malignant chondrocytes and fibroblasts was found to be decreased [8].

Detailed knowledge of the molecular mechanism of new potential chemotherapeutic agents is paramount in order to predict safety, efficacy, possible adverse effects, and resistance [9]. Key tools to reveal the molecular mode of action are microarrays and RNA-sequencing, allowing identification of differentially expressed genes (DEGs).

Antimitotic drugs disrupt the cell cycle progression of tumor cells. The purpose of the cell cycle is to duplicate the DNA accurately and to segregate the copies into two identical daughter cells. In brief, the cell cycle is divided into G1-phase, S-phase, G2-phase and M-phase. It is a complex process whose successful progress is controlled by many checkpoints in healthy cells. If a checkpoint is activated, for example, due to DNA damage, the cell cycle is arrested until either DNA repair or programmed cell death occurs [10]. In tumor cells, the checkpoints are often defective, making them selective for drugs that target these checkpoints [11]. Possible targets are cyclin-dependent kinases (CDKs), the regulators of cell cycle progression [12]. CDKs form complexes with cyclins [13] and can be inhibited by the cyclin-dependent kinase inhibitor 1A (CDKN1A, p21). Since its discovery in 1993 [14], research on involvement of CDKN1A in cell cycle, cell differentiation, and apoptosis is of great interest [15, 16].

PC-3 is a human prostate cancer cell line, representing the castration-resistant prostate cancer. It develops in 10–20% of patients with prostate cancer where androgen deprivation therapy has failed [17]. The cell line PC-3 is a stable and well-characterized androgen-independent human cell line. The in vivo behavior of this cell line is also well known, so adapting research on FX-9 to in vivo experiments would be simplified.

The aim of the present study was to characterize in vitro the molecular mode of action of FX-9 by gene expression level in a stable in vitro model system (PC-3 cell line) and verification of selected targets at protein level.



FX-9 (3-(p-Tolyl)isoquinolin-1-amine) was synthesized by Feng and Wu [1]. The 10 mM stock solution was dissolved in dimethylsulfoxide (DMSO; Merck KGaA, Darmstadt, Germany) and stored at − 20 °C. For the experiments a final concentration of 5 μM was used in accordance with our previous results [8] and prepared immediately prior to each experiment.

Cell lines and cell culture

PC-3 is an androgen-insensitive human cell line of a bone metastasis from a prostate carcinoma of a 62-year-old man [18]. The cell line was cultivated in 25 cm2 cell culture flasks in medium 199 (Gibco™, Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 10% fetal bovine serum superior (Biochrom GmbH, Berlin, Germany) and 2% penicillin-streptomycin (Biochrom GmbH). The cells were cultivated at 37 °C and 5% CO2 in a humidified atmosphere.

RNA-isolation and –integrity

The cell lines were seeded at a density of 600,000 cells in 5 ml culture medium in 25 cm2 cell culture flasks and incubated for 12 h at 37 °C and 5% CO2 in a humidified atmosphere. The cells were exposed to 5 μM FX-9 for 6 and 12 h, cultured in an incubator at 37 °C and 5% CO2 in a humidified atmosphere. The concentration was selected as it had shown significant anti-proliferative effects on PC-3 in our previous study [8]. Time points were chosen in accordance with our previous cell biological results characterizing early transcriptome alteration before induction of cell death. Untreated cells served as control. The cells were detached with a cell scraper and collected in phosphate-buffered saline. The cell suspension was transferred into tubes and centrifuged at 20 °C and 150 x g for 10 min. The supernatant was discarded, the cell pellets were lyzed using 600 μl chaotropic buffer (RLT plus buffer, Qiagen GmbH, Hilden, Germany). The lyzates were transferred into cryotubes and stored at − 80 °C. RNA extraction was performed using the RNeasy Plus Kit (Qiagen GmbH) including a DNA removal step in accordance with the manufacturer’s protocol. The RNA samples were quantified spectrophotometrically (Nanodrop 1000 (Thermo Fisher Scientific, Inc., Waltham, MA, USA)) and diluted to a concentration of 70 ng per microliter for RNA integrity analysis (Agilent RNA 6000 Nano Chip using Bioanalyzer 2100 instrument (Agilent Technologies, Inc., Santa Clara, Ca, USA)). Samples were prepared as independent biological replicates. All samples showed an RNA integrity number of 10.0.

Gene expression level profiling

200 ng RNA was used as starting material in the GeneChipR Whole Transcript Sense Target Labeling protocol (Affymetrix, Thermo Fisher Scientific, Inc.). The microarray hybridization was performed using the Affymetrix Clariom™ S Array Kit in accordance with the manufacturer’s instructions (Affymetrix, Thermo Fisher Scientific, Inc.): in detail, the so called WT (Whole Transcriptome) protocol started with first strand synthesis by introducing T7 promoter tags to all RNA molecules using N6 3` ends. After strand replacement in accordance with Eberwine, non-labeled aRNA (antisense RNA) was produced by in vitro transcription in agreement with the linear amplification of all RNA molecules without a 3’bias. After an aRNA cleanup (magnet bead based), a new strand identical single-strand DNA was produced using the aRNA as template by adding random primers and deoxyribonucleoside 5′-triphosphates (dNTPs). In the meantime, a certain amount of dTTP was replaced by dUTP. After removing the aRNA by RNaseH digestion and clean-up (magnet bead based), this enabled an enzymatic endpoint fragmentation. Therefore, uracyldeglycosidase removed the uracils in combination with APE1 (apurinic apyrimidinic endonuclease 1), which is cleaved the deuracylized phosphodiester backbone of the single strand DNA molecules. Desoxynucleotidyltransferase was added to the DNA labeling reagent (Biotin-11-dXTP) to the 3` ends of the single strand DNA fragments. The hybridization was carried out overnight (16 h) at 45 °C in the GeneChipR Hybridization Oven 645 (Affymetrix, Thermo Fisher Scientific, Inc.). Washing and staining protocols, including an antibody amplification, were applied by the GeneCip Fluidis Station 450. The microarrays were scanned using the GeneChip Scanner 3000 7G (Affymetrix, Thermo Fisher Scientific, Inc.) at 0.7 μm resolution.

Analysis of the microarray data

Affymetrix Clariom™ S Arrays interrogate more than 20,800 genes using about 800,000 probes. The data was analyzed by the Transcriptome Analysis Console (TAC) version (Applied Biosystems, Thermo Fisher Scientific, Inc.) with the implemented SST-RMA normalization algorithm. Replicate groups were summarized by LIMMA statistics. Differentially expressed genes (DEGs) were identified using filter parameters fold change (FC) < 2 or < − 2, LIMMA p-value < 0.05, and FDR-value < 0.05.

Analysis of signaling pathways and biological processes

To analyze the cellular signaling pathways effected by FX-9, the total number of DEGs were examined in the known pathway network Reactome [19]. Analyzing DEGs by gene ontology functional processes was performed via the gene network Database for Annotation, Visualization and Integrated Discovery (DAVID, DAVID Bioinformatics Resources 6.8) [20]. DEGs enriched signaling pathways with an FDR-value < 0.05 were considered for further analysis.

Immunocytochemical (ICC) staining

PC-3 cells were seeded at a density of 5 × 106 cells per 75 cm2 culture flask and were incubated over night to adhere. After exposure to 5 μM FX-9 or cell culture medium for control for 12 h or 24 h, the cells were harvested by TrypLE™ Express Enzyme (Gibco™, Thermo Fisher Scientific, Inc.) and pelleted in 1.5 ml tubes by centrifugation (20 °C, 150 x g, 10 min). The cell pellets were fixed in 1 ml cold 4% paraformaldehyde and stored at 4–8 °C for a maximum of 7 days until embedding in paraffin. After slicing the paraffin-embedded cell pellets, they were mounted on slides. Thermal antigen demasking in citrate buffer was performed for 20 min in a microwave. To exclude non-specific binding, the slides were blocked with 20% goat serum for 20 min. This was followed by incubation with mouse monoclonal primary antibodies p21 Waf1/Cip1 (diluted 1:100, sc-6246, Santa Cruz Biotechnology, Inc., Dallas, TX, USA,), E2F-1 (diluted 1:200, sc-251, Santa Cruz Biotechnology, Inc.,), PAI-1 (diluted 1:50, sc-5297, Santa Cruz Biotechnologys, Inc.), and rabbit monoclonal primary antibody NFkB2/NFkB p100 (diluted 1:200, JM82–03, Novus Biologicals, LLC, Littleton, CO, USA) at 4 °C over night. After a 45-min incubation period with biotinylated secondary antibodies goat anti-mouse (diluted 1:200, BA-9200, Vector Laboratories, Inc., Burlingame, CA, USA) or goat anti-rabbit (diluted 1:200, BA-1000, Vector Laboratories, Inc.,) indirect avidin-biotin-peroxidase staining with VECTASTAIN®Elite® ABC-kit (Vector Laboratories, Inc.) was performed in accordance with manufacturer’s protocol. Reaction was visualized by incubation in 0.1 g 3,3′-diaminobenzidine tetrahydrochloride (DAB, Acros Organics, BVBA, Fair Lawn, NJ, USA) in 200 ml PBS and counterstaining was performed with hematoxylin. The experiment was performed in triplicates. Staining intensities and the fraction of positively stained cells were scored as proposed by Sorenmo et al. [21] and Pagliarone et al. [22] by an experienced and blinded pathologist.


FX-9 caused changes in gene expression level profile at 6-h and 12-h exposure

Principal component analysis (PCA) with TAC software showed clustering of the three different sample groups: control, 6-h and 12-h samples (Fig. 1). A total of 21,448 genes were analyzed by the microarray. PC-3 expressed 18,722 of these genes, and after 6-h exposure to 5 μM FX-9, 179 genes were differentially expressed compared to untreated controls. In comparison to the total number of genes analyzed, this represented 0.83%. In relation to the genes expressed in PC-3, the percentage of DEGs was 5.24%. Of these DEGs, 116 genes showed increased expression with fold change ranging from 2 to 18.05. The expression of 78 genes was decreased with fold change between − 2 and − 3.41.Gene expression analysis after exposure to 5 μM FX-9 over a 12-h period revealed a total of 145 DEGs compared to non-treated control samples. This represented that 0.68% of the total analyzed genes and 0.75% of the 19,280 expressed genes in PC-3 in the 12-h samples. The expression of 78 genes was increased between fold change of 2 and 7.92 and the expression of 67 genes was decreased within fold change ranging from − 2 to − 5.14. On comparing DEGs of 6-h and 12-h samples, overlapping of 53 DEGs was shown. The annotation of the DEGs of the 6-h and 12-h samples to signaling pathways is described in the following paragraphs of the results.

Fig. 1

A: PCA mapping: Three-dimensional diagram: clear differentiation of the three sample groups showing high consistency within the individual replicates in the original dataset. B: Venn diagram: Number of DEGs in 6-h and 12-h samples are displayed and overlapping DEGs (n = 53) are highlighted in purple. C and D: Volcano plots after 6-h and 12-h exposure of 5 μM FX-9. Plots display the FC against the negative decadic logarithm of the FDR-value. Color code: red FC > 2, green FC < − 2, both with LIMMA p-value < 0.05, and FDR-value < 0.05

FX-9 induced Reactome-pathways of the immune system after 6-h exposure and in cell cycle pathways after 12-h exposure

After identifying the DEGs, signaling pathway analysis was performed using the gene database Reactome. The total list of DEGs was submitted to Reactome, where the DEGs were mapped to signaling pathways and analyzed for over-represented signaling pathways. The analysis was performed statistically using a hypergeometric distribution that identified enriched signaling pathways in the submitted data. Fifteen signaling pathways passed the criteria of FDR-value < 0.05. Eight of these fifteen enriched signaling pathways can be assigned to the superpathway “immune system” (Table 1). These signaling pathways were mainly activated by increasingly expressed genes. Two signaling pathways of the superpathway “cell cycle” were enriched by upregulation of CDKN1A (FC 3.88, Fig. 2). The pathway “TP53 regulates transcription of genes involved in G1 cell cycle arrest” belongs to the superpathway gene expression, describes the involvement of genes in G1-phase cell cycle arrest and was enriched by activation of E2F7 (FC 2.56). Two signaling pathways were activated by increasingly expressed genes and functionally belong to the superpathway “signal transduction”. The signaling pathway “insulin-like growth factor-2 mRNA binding proteins (IGF2BPs/IMPs/VICKZs) bind RNA” belongs to the superpathway “RNA metabolism”, and was enriched by two DEGs. The signaling pathway “cellular senescence”, which belongs to the superpathway “cellular response to external stimuli” was activated by seven DEGs.

Table 1 Reactome top 15 enriched signaling pathways after 6-h exposure of FX-9
Fig. 2

DEGs belonging to Reactome pathways “Immune System”, and “Cell Cycle” after 6-h and 12-h FX-9 exposure. Numbers given for each gene display the FC (in linear space) of 6-h and 12-h samples versus the control. Values highlighted in red or blue indicate significantly higher or lower expression. Non-highlighted values are not significantly different (LIMMA p-value < 0.05, and FDR-value < 0.05)

Analysis of DEGs comparing control with 12-h exposure of 5 μM FX-9 showed 119 affected signaling pathways with an FDR-value < 0.05. Of these, the top fifteen enriched signaling pathways were considered for further analysis (Table 2). Seven signaling pathways assigned to the superpathway “cell cycle” were enriched by DEGs. These signaling pathways were inhibited by genes involved in the transition of cells from the G1- to the S-phase, such as CCNE2, CDC6, CDKN1A, CDT1, E2F1, E2F2, MCM3 and MCM6 (Fig. 2). The two pathways belonging to the superpathway “gene expression” are also involved in the cell cycle. These were enriched by DEGs CCNE2, CDKN1A, E2F1, E2F2, and E2F7. DEGs enriched three signaling pathways belonging to the superpathway “cellular response to external stimuli”. The signaling pathways “DNA replication” and “transcriptional regulation of granulopoiesis” were enriched by DEGs similar to those in the superpathway “cell cycle”. In the superpathway “RNA metabolism”, the signaling pathway “Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA” was enriched by upregulation of CD44.

Table 2 Reactome top 15 enriched signaling pathways after 12-h exposure of FX-9

FX-9 induced time-dependent differences in the biological processes of inflammatory response and G1/S transition of mitotic cell cycle

To assign DEGs to the context of the affected biological processes in the cells, the platform DAVID was used. Biological processes with an FDR-value < 0.05 were included in this analysis. The processes “inflammatory response”, “angiogenesis, positive regulation of cell migration”, “positive regulation of angiogenesis”, “extracellular matrix organization”, and “negative regulation of apoptotic process” were enriched by DEGs at both time points (Table 3). The process with the lowest FDR-value of 0.00013 in the 6-h samples was the “inflammatory response” affected by 18 DEGs. This process was also enriched in the 12-h samples, but with a higher FDR-value of 0.027 and 12 DEGs.

Table 3 DAVID analysis functional annotation, gene ontology, 6-h and 12-h FX-9 exposure

After 6-h exposure of FX-9, genes with increased expression enriched the processes “I-kappaB kinase/NF-kappaB signaling”, “positive regulation of NF-kappaB transcription factor activity”, “negative regulation of cell proliferation”, and “cell adhesion”. In the biological process “positive regulation of transcription from RNA polymerase II promoter”, of a total of 24 DEGs, 18 showed positive and 6 negative FC. The biological process “positive regulation of nitric-oxide synthase biosynthetic process” was also enriched by nine DEGs. The biological process “positive regulation of ERK1 and ERK2 cascade” was enriched by upregulated genes with two exceptions. The biological processes “G1/S transition of mitotic cell cycle” and “positive regulation of endothelial cell proliferation” were only enriched in the 12-h samples after FX-9 exposure. “G1/S transition of mitotic cell cycle” was enriched with an FDR-value of 0.0006 by nine genes, including CDC6, CDT1, CDKN1A, CCNE2, MCM3, and MCM6.

FX-9 application increased the amount of CDKN1A (p21) protein expressing cells and intensity of NFKB2 expression

Due to the enrichment of DEGs in cell cycle signaling pathways from 12-h exposure, this time point was chosen to verify the transcriptome data of CDKN1A, E2F1, SERPINE1, and NFKB2 at protein level by immunocytochemistry. These genes were selected based on their different functions representing the changes at the molecular biology level. CDKN1A is a cell cycle inhibitor, E2F1 is an important transcription factor for entry in the S-phase, SERPINE1 plays a role in senescence, and NFKB2 is a marker for DNA damage [23,24,25,26]. As CDKN1A, E2F1 and NFKB2 are assigned to the signaling pathways “immune system” or “cell cycle”, their gene expressions were visualized in Fig. 2. SERPINE1 is an exception and not visualized as it is not assigned to these pathways. It was, however, differentially expressed (6-h exposure to FX-9 FC 5.53, 12-h exposure to FX-9 FC 3.05) and selected as it plays a role in cellular senescence [23]. The time point of 24-h FX-9 exposure was also chosen to monitor the further progression of those proteins.

After 12-h exposure to FX-9, no changes in the amount of CDKN1A-expressing cells, and decreased intensity from moderate to weak-moderate were shown (Table 4). Positively stained E2F1 expressing cells showed slightly stronger intensity but no increase in the fraction of positively stained cells. SERPINE1 expression in the cells had a weak intensity, and the fraction of positively stained cells increased. NFKB2 was expressed by 100% of the cells and showed an increase from moderate-strong to strong intensity after exposure to FX-9. After 24 h of exposure of cells to FX-9, the fraction of CDKN1A-expressing cells increased, while the intensity was constant. In contrast, the fraction of NFKB2-expressing cells showed no variation, although the intensity increased from weak-moderate to moderate-strong. E2F1 and SERPINE1 expressing cells showed no differences in the fraction of positively stained cells and intensity comparing the control cells with the cells exposed to 5 μM.

Table 4 ICC-staining comparing control cells with cells after 12-h or 24-h exposure to 5 μM FX-9


The aim of the present study was to characterize in vitro the molecular mode of action of FX-9 by gene expression level in a stable in vitro model system (PC-3 cell line) and to verify selected targets at protein level.

At cellular level, pro-apoptotic characteristics of FX-9 could be demonstrated. Gene expression level profiling resulted in DEGs of < 1% of total genes tested comparing the control with the 6-h or 12-h FX-9 exposure. Therefore, the investigation of initial drug-mediated events leading to apoptosis before the expected apoptotic signal overflow was possible. Analyzing the DEGs after 6-h FX-9 exposure showed an inflammatory response, and after the 12-h exposure, cell cycle disturbance. Interestingly, the potent cell cycle inhibitor CDKN1A and transcription factor E2F7 were activated in the 6-h samples, potentially causing the cell cycle-related response in the 12-h samples.

The early response to FX-9 was a stress-induced inflammatory response by activating the nuclear factor-kappa B (NF-κB) signaling pathway. NF-κB includes a family of transcription factors, which have key roles in inflammatory and immune responses [27]. The canonical (classical) NF-κB signaling pathway is activated by stimuli from various immune receptors [27]. Response via the non-canonical (alternative) NF-κB signaling pathway is activated by only a few members of the tumor necrosis factor superfamily receptors and pathogens like viruses and bacteria [28]. MAP3K14 (NIK) has normally a steady level expression in the cytoplasm, and accumulates in response to those activating stimuli. This activates IKKα and phosphorylation of p100 to p52, which forms a complex with RelB [29]. The RelB/p52 complex translocates into the nucleus and activates the transcription of the target genes (Fig. 1). In our study, FX-9 activated the central genes of non-canonical NF-κB signaling such as MAP3K14 (NIK), RelB, and NFKB2. NF-κB downstream target genes of following classes were activated: cytokines/chemokines and their modulators (CCL20, IL1B, IL6, IL8 (CXCL8)), immunoreceptors (TNFRSF9), cell adhesion molecules (CD44), regulators of apoptosis (BIRC2, BIRC3), growth factors, ligands and their modulators (FSTL3, INHBA, THBS1), transcription factors and regulators (NFKB2, RELB, NFKBIA, TNFAIP3), and miscellaneous (CDKN1A, GADD45B) [30]. Of these genes, TNFAIP3, encoding protein A20, and NFKBIA, encoding protein IκBα, mediate a negative feedback control, resulting in a self-limitating response [31, 32]. In our study, NF-κB activation and inflammatory response were more prominent in the 6-h than in the 12-h samples, which could be caused by the negative feedback mechanism. Activation of NF-κB can mediate anti-apoptotic signals, which leads to survival of the cells [33]. As an example, IL-6 is known for playing a part in chemoresistance and metastasis of aggressive prostate cancer [34]. IL-6 gene expression was increased with an FC of 2.13 after 6 h exposure to FX-9, however, gene expression was not significantly affected after 12-h exposure to FX-9 (FC 1.67). Reduced activation of those signals after 12-h exposure of FX-9 could explain its time dependent pro-apoptotic and anti-proliferative effect observed in a previous study of ours in different cell lines [8].

After 12-h FX-9 exposure, signaling pathways of cell cycle regulation were enriched by DEGs. FX-9 exposure increases the cell cycle inhibitor CDKN1A, which encodes protein p21, providing multiple functions, for example, cell cycle arrest in response to drug induced DNA-damage [35]. In our study, similar to other studies, combined upregulation of CDKN1A and E2F7 was shown, and interaction of these genes can repress E2F1, a transcription factor for many key proteins, which are essential for G1/S transition [36,37,38]. Blocking of E2F1 transcriptional activity inhibits the expression of its target genes [39]. In the present study, E2F1 was decreased after 12-h exposure to FX-9. The target genes CDC6 [40], CDT1 [41], CCNE2 [42], MCM3 und MCM6 [43] were also inhibited (Fig. 2). These genes are essential for transition from the G1-phase to the S-phase, and relevant for forming the pre-replicative complex [44]. Inhibiting these can provide a G1 cell cycle arrest and suppression of DNA replication [45, 46]. These results confirmed the antimitotic character of FX-9 on prostate carcinoma cells. In contrast to the gene expression level profiling, ICC showed a stable E2F1 protein expression. E2F1 protein is inactivated by binding to hypophosphorylated retinoblastoma protein (RB) [47]. Phosphorylation of RB by CDK4/cyclin D in combination with CDK2/cyclin E in the late G1-phase releases E2F1, which subsequently activates genes for G1/S transition [48]. It is possible, that FX-9 inhibited this phosphorylation and that ICC staining detected the inactive E2F1 protein in the RB/E2F1 complex.

FX-9 causes enrichment of DEGs in signaling pathways of cellular senescence in both time points. Morphological studies by Schille et al. showed evidence of a senescent phenotype at the earliest after 12-h FX-9 exposure [8]. Cellular senescence is a persistent cytostasis with a distinct morphological and biochemical phenotype induced by stress stimuli like strong mitotic signals or non-telomeric DNA damage [49]. SERPINE1 is a marker for senescence and essential for maintenance of this phenotype in fibroblasts [50] and was activated in the present study. Upregulation of the protein PAI-1, encoded by SERPINE1, occurred after 12-h FX-9 exposure and showed a stable expression in the 24-h samples compared to the control. This could be due to the fact that in the 24-h samples, 100% of control cells already expressed PAI-1, so no increase in the fraction of positively stained cells could occur. Therapy-induced senescence can be induced by anticancer agents [51], for example, antimitotic agents like microtubule poisons [52]. Senescence is additional evidence for the antimitotic nature of FX-9. Tumor cells could escape from cell cycle arrest and re-enter the cell cycle (mitotic slippage), usually resulting in those senescent cells or cell death in the G1-phase [53]. On a cellular level, this was confirmed by enlarged multinucleated cells [8]. These cells bear tumorigenic potential, which suggests careful consideration should be given to the application of such antimitotic agents [52].


The molecular acting mechanism of FX-9 was elucidated. Correlation of the observed gene expression changes and the biological response confirmed the antimitotic character of FX-9. Specifically, the enrichment of cell cycle associated DEGs regulating the transition from G1-phase to S-phase supports the thesis of an FX-9 induced G1-phase arrest. Described effects of FX-9 like induction of cell cycle inhibitor CDKN1A, activation of NF-κB signaling pathway and senescence can be caused by DNA damage [24, 26, 49]. For the substance family of FX-9, the quinolines, topoisomerase inhibition is a possible mechanism of action, which can cause DNA double strand breaks [54]. The DNA-damaging character and possible topoisomerase inhibition of FX-9 are worth being further evaluated.

Availability of data and materials

The raw datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. The Data of DEGs, which were used for the analysis are available in the additional supporting files.



Cyclin Dependent Kinase Inhibitor 1A


Cyclin-dependent kinases


Database for Annotation, Visualization and Integrated Discovery


Differential expressed genes


Fold change


False discovery rate




Principal component analysis


Transcriptome Analysis Console


  1. 1.

    Feng JB, Wu XF. Potassium tert-Butoxide-promoted synthesis of 1-Aminoisoquinolines from 2-Methylbenzonitriles and Benzonitriles under catalyst-free conditions. Adv Synth Catal. 2016;358(13):2179–85.

    CAS  Article  Google Scholar 

  2. 2.

    Gutteridge CE, Hoffman MM, Bhattacharjee AK, Milhous WK, Gerena L. In vitro efficacy of 7-benzylamino-1-isoquinolinamines against plasmodium falciparum related to the efficacy of chalcones. Bioorg Med Chem Lett. 2011;21(2):786–9.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Gößnitzer E, Punkenhofer A, Amon A, Favre B. Novel high energy intermediate analogues with triazasterol-related structures as inhibitors of ergosterol biosynthesis: III. Synthesis and antifungal activity of N4-alkyl-1, 6, 7, 11b-tetrahydro-2H-pyrimido [4, 3-a] isoquinolin-4-amine salts. Eur J Pharm Sci. 2003;19(2–3):151–64.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Yang SH, Van HTM, Le TN, Khadka DB, Cho SH, Lee K-T, et al. Development of 3-aryl-1-isoquinolinamines as potent antitumor agents based on CoMFA. Eur J Med Chem. 2010;45(11):5493–7.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Chung K-S, Choi H-E, Shin J-S, Cho Y-W, Choi J-H, Cho W-J, et al. 6, 7-Dimethoxy-3-(3-methoxyphenyl) isoquinolin-1-amine induces mitotic arrest and apoptotic cell death through the activation of spindle assembly checkpoint in human cervical cancer cells. Carcinogenesis. 2013;34(8):1852–60.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Khadka DB, Woo H, Yang SH, Zhao C, Jin Y, Le TN, et al. Modification of 3-arylisoquinolines into 3, 4-diarylisoquinolines and assessment of their cytotoxicity and topoisomerase inhibition. Eur J Med Chem. 2015;92:583–607.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Roolf C, Saleweski J-N, Stein A, Richter A, Maletzki C, Sekora A, et al. Novel isoquinolinamine and isoindoloquinazolinone compounds exhibit antiproliferative activity in acute lymphoblastic leukemia cells. Biomol Ther. 2019;27(5):492–501.

    CAS  Article  Google Scholar 

  8. 8.

    Schille JT, Nolte I, Packeiser E-M, Wiesner L, Hein JI, Weiner F, et al. Isoquinolinamine FX-9 exhibits anti-mitotic activity in human and canine prostate carcinoma cell lines. Int J Mol Sci. 2019;20(22):5567.

    CAS  Article  PubMed Central  Google Scholar 

  9. 9.

    Stears RL, Martinsky T, Schena M. Trends in microarray analysis. Nat Med. 2003;9(1):140–5.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol. 2008;9(4):297–308.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Warrener R, Beamish H, Burgess A, Waterhouse NJ, Giles N, Fairlie DP, et al. Tumor cell-specific cytotoxicity by targeting cell cycle checkpoints. FASEB J. 2003;17(11):1–21.

    CAS  Article  Google Scholar 

  12. 12.

    Ingham M, Schwartz GK. Cell-cycle therapeutics come of age. J Clin Oncol. 2017;35(25):2949–59.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1(3):222–31.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75(4):817–25.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Kreis N-N, Louwen F, Yuan J. The multifaceted p21 (Cip1/Waf1/CDKN1A) in cell differentiation, migration and cancer therapy. Cancers. 2019;11(9):1220.

    CAS  Article  PubMed Central  Google Scholar 

  16. 16.

    Dutto I, Tillhon M, Cazzalini O, Stivala LA, Prosperi E. Biology of the cell cycle inhibitor p21 CDKN1A: molecular mechanisms and relevance in chemical toxicology. Arch Toxicol. 2015;89(2):155–78.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Kirby M, Hirst C, Crawford E. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–92.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Kaighn M, Narayan KS, Ohnuki Y, Lechner J, Jones L. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investig Urol. 1979;17(1):16–23.

    CAS  Google Scholar 

  19. 19.

    Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2020;48(D1):D498–503.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Jiao X, Sherman BT, Huang DW, Stephens R, Baseler MW, Lane HC, et al. DAVID-WS: a stateful web service to facilitate gene/protein list analysis. Bioinformatics. 2012;28(13):1805–6.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Sorenmo K, Goldschmidt M, Shofer F, Goldkamp C, Ferracone J. Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Vet Comp Oncol. 2004;2(1):13–23.

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Pagliarone S, Frattone L, Pirocchi V, Della Salda L, Palmieri C. Altered expression of p53, but not Rb, is involved in canine prostatic carcinogenesis. Res Vet Sci. 2016;105:195–9.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Kortlever RM, Bernards R. Senescence, wound healing, and cancer: the PAI-1 connection. Cell Cycle. 2006;5(23):2697–703.

    CAS  Article  Google Scholar 

  24. 24.

    Habraken Y, Piette J. NF-κB activation by double-strand breaks. Biochem Pharmacol. 2006;72(9):1132–41.

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Chen H-Z, Tsai S-Y, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 2009;9(11):785–97.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair. 2016;42:63–71.

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell. 2008;132(3):344–62.

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Sun S-C. The non-canonical NF-κB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17(9):545–58.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Ling L, Cao Z, Goeddel DV. NF-κB-inducing kinase activates IKK-α by phosphorylation of Ser-176. Proc Natl Acad Sci U S A. 1998;95(7):3792–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Gilmore TD. NF-kB Target Genes, verfügbar in Boston University, Biology. zitiert am 12.04.2021:.

  31. 31.

    Huxford T. Huang D-b, Malek S, Ghosh G. the crystal structure of the IκBα/NF-κB complex reveals mechanisms of NF-κB inactivation. Cell. 1998;95(6):759–70.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Lork M, Verhelst K, Beyaert R. CYLD, A20 and OTULIN deubiquitinases in NF-κ B signaling and cell death: so similar, yet so different. Cell Death Differ. 2017;24(7):1172–83.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol. 2002;3(3):221–7.

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem. 2005;95(3):497–505.

    CAS  Article  PubMed  Google Scholar 

  35. 35.

    Cazzalini O, Scovassi AI, Savio M, Stivala LA, Prosperi E. Multiple roles of the cell cycle inhibitor p21CDKN1A in the DNA damage response. Mutat Res. 2010;704(1–3):12–20.

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Carvajal LA, Hamard P-J, Tonnessen C, Manfredi JJ. E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression. Genes Dev. 2012;26(14):1533–45.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Aksoy O, Chicas A, Zeng T, Zhao Z, McCurrach M, Wang X, et al. The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence. Genes Dev. 2012;26(14):1546–57.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Schlereth K, Heyl C, Krampitz A-M, Mernberger M, Finkernagel F, Scharfe M, et al. Characterization of the p53 cistrome–DNA binding cooperativity dissects p53's tumor suppressor functions. PLoS Genet. 2013;9(8):e1003726.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Sheldon LA. Inhibition of E2F1 activity and cell cycle progression by arsenic via retinoblastoma protein. Cell Cycle. 2017;16(21):2058–72.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Ohtani K, Tsujimoto A. Ikeda M-a, Nakamura M. regulation of cell growth-dependent expression of mammalian CDC6 gene by the cell cycle transcription factor E2F. Oncogene. 1998;17(14):1777–85.

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Yoshida K, Inoue I. Regulation of geminin and Cdt1 expression by E2F transcription factors. Oncogene. 2004;23(21):3802–12.

    CAS  Article  PubMed  Google Scholar 

  42. 42.

    Stanelle J, Stiewe T, Theseling CC, Peter M, Pützer BM. Gene expression changes in response to E2F1 activation. Nucleic Acids Res. 2002;30(8):1859–67.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Poppy Roworth A, Ghari F, La Thangue NB. To live or let die–complexity within the E2F1 pathway. Mol Cell Oncol. 2015;2(1):e970480.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Cook JG, Chasse DA, Nevins JR. The regulated association of Cdt1 with minichromosome maintenance proteins and Cdc6 in mammalian cells. J Biol Chem. 2004;279(10):9625–33.

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Wu Z, Cho H, Hampton GM, Theodorescu D. Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis. Neoplasia. 2009;11(1):66–76.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Li C, Ge M, Chen D, Sun T, Jiang H, Xie Y, et al. RPL21 siRNA blocks proliferation in pancreatic cancer cells by inhibiting DNA replication and inducing G1 arrest and apoptosis. Front Oncol. 2020;10:1730.

    Article  PubMed  PubMed Central  Google Scholar 

  47. 47.

    Helin K, Harlow E, Fattaey A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol Cell Biol. 1993;13(10):6501–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  48. 48.

    Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998;18(2):753–61.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  49. 49.

    Campisi J, Di Fagagna FDA. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8(9):729–40.

    CAS  Article  PubMed  Google Scholar 

  50. 50.

    Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol. 2006;8(8):877–84.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Zhang B, Lam EWF, Sun Y. Senescent cells: a new Achilles’ heel to exploit for cancer medicine? Aging Cell. 2019;18(1):e12875.

    CAS  Article  PubMed  Google Scholar 

  52. 52.

    Cheng B, Crasta K. Consequences of mitotic slippage for antimicrotubule drug therapy. Endocr Relat Cancer. 2017;24(9):T97–T106.

    CAS  Article  PubMed  Google Scholar 

  53. 53.

    Mc Gee MM. Targeting the mitotic catastrophe signaling pathway in cancer. Mediat Inflamm. 2015;2015:146282–13.

    CAS  Article  Google Scholar 

  54. 54.

    Afzal O, Kumar S, Haider MR, Ali MR, Kumar R, Jaggi M, et al. A review on anticancer potential of bioactive heterocycle quinoline. Eur J Med Chem. 2015;97:871–910.

    CAS  Article  PubMed  Google Scholar 

Download references


The authors want to thank Katharina Klose, Eva-Maria Packeiser, and Kerstin Rohn for excellent technical support and Frances Sherwood-Brock for spell-checking the manuscript.


Not applicable. Open Access funding enabled and organized by Projekt DEAL.

Author information




FW, HME, and IN conceived and designed the study. FW, and JTS designed the experiments. FW, JTS, and DK conducted microarray experiments, and FW performed immunocytochemistry-staining. FW analyzed and interpreted the microarray data and MHT performed analysis of data of immunocytochemistry staining. FW, and in parts DK drafted the work. JTS, DK, XFW, MB, CJ, MHT, HME, and IN reviewed and edited the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to I. Nolte.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Additional file 2: Supplementary Fig. 1

Immunocytochemistry staining of control cells and cells after exposure to 5 μM FX-9 for 12 h.

Additional file 3: Supplementary Fig. 2

Immunocytochemistry staining of control cells and cells after exposure to 5 μM FX-9 for 24 h.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Weiner, F., Schille, J.T., Koczan, D. et al. Novel chemotherapeutic agent FX-9 activates NF-κB signaling and induces G1 phase arrest by activating CDKN1A in a human prostate cancer cell line. BMC Cancer 21, 1088 (2021).

Download citation


  • Isoquinolinamine FX-9
  • Antimitotic agent
  • Microarray analysis
  • NF-κB signaling
  • G1-phase arrest
  • Prostate cancer